The antibacterial effect of fatty acids on Helicobacter pylori infection.
10.3904/kjim.2016.31.1.30
- Author:
Sung Woo JUNG
1
;
Sang Woo LEE
Author Information
1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. leesw@kumc.or.kr
- Publication Type:Review
- Keywords:
Helicobacter pylori;
Fatty acids;
Anti-bacterial agents;
Liposomes;
Drug delivery systems
- MeSH:
Animals;
Anti-Bacterial Agents/administration & dosage/*therapeutic use;
Drug Delivery Systems;
Fatty Acids/administration & dosage/*therapeutic use;
Helicobacter Infections/diagnosis/*drug therapy/microbiology;
Helicobacter pylori/*drug effects/pathogenicity;
Humans;
Liposomes;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2016;31(1):30-35
- CountryRepublic of Korea
- Language:English
-
Abstract:
Eradication of Helicobacter pylori is recommended for the management of various gastric diseases, including peptic ulcers and mucosa-associated lymphoid tissue lymphoma. Because of the increasing prevalence of antibiotic resistance, the eradication rates of antibiotic-based therapies have decreased. Therefore, alternative treatments should be considered. The antibacterial properties of fatty acids (FAs) have been investigated in various organisms, including H. pylori. Some FAs, particularly polyunsaturated FAs, have been shown to have bactericidal activity against H. pylori in vitro; however, their antibacterial effects in vivo remain controversial. Poor solubility and delivery of FAs may be important reasons for this discrepancy. Recently, a series of studies demonstrated the antibacterial effects of a liposomal formulation of linolenic acid against H. pylori, both in vitro and in vivo. Further research is needed to improve the bioavailability of FAs and apply them in clinical use.
